Boxer Capital has invested in Enliven Therapeutics, a biotech group. Boxer was among 14 investors committing $165 million to the Colorado-based group.
Subscribe
You will need a Premium+ Subscription to read this article.
Exclusive news, analysis and research on global family enterprise and private investment offices
Already have an account? Sign in
Already have an account? Sign in
You've reached the end.
Continue reading free articles by registering as a Member.
Or choose a Premium Plan.
Already have an account? Sign in
